305 results on '"Gastinne, T"'
Search Results
2. AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
3. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review
4. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas
5. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
6. Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies
7. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
8. La place de la TEP au FDG dans l’évaluation des lymphomes en 2012
9. Bilan d’extension et suivi dans le traitement des lymphomes
10. Staging and monitoring in the treatment of lymphomas
11. The role of FDG-PET scanning in assessing lymphoma in 2012
12. S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY
13. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.
14. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY
15. 18F-fluorodeoxyglucose–positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group
16. Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT
17. P56 - Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation: COMPARABLE OUTCOMES AMONG ADULT PATIENTS ALLOTRANSPLANTED FOR MYELODYSPLASTIC SYNDROME USING HAPLOIDENTICAL, MATCHED UNRELATED OR MATCHED SIBLING DONORS: A SINGLE-CENTER STUDY.
18. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
19. Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier
20. Chemotherapy-driven dysbiosis in the intestinal microbiome
21. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center
22. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)
23. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance
24. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation
25. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity
26. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation
27. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation
28. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients
29. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis – current evidence and potential clinical applications
30. FEASABILITY OF A SEQUENTIAL CONDITIONING REGIMEN COMBINING CLOFARABINE/CYTARABINE CHEMOTHERAPY FOLLOWED BY A FLUDARABINE/CYCLOPHOSPHOMIDE/ATG-BASED RIC REGIMEN BEFORE ALLO-SCT IN ADULTS WITH PRIMARY/RELAPSED REFRACTORY MDS/AML: A PILOT STUDY: PH-AB260
31. FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES
32. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY
33. LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDY
34. AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS
35. Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.
36. EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY.
37. Traitement des lymphomes de Hodgkin localisés
38. Safety and efficacy of rituximab in steroid-refractory chronic GVHD
39. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors
40. Repetitive patientsʼ satisfaction survey in a JACIE-accredited centre: the Nantes University Hospital experience, France: N1252
41. Fludarabine, low-dose busulfan and antithymocyte globulin compared to fludarabine and low-dose TBI for reduced-intensity conditioning prior to allogeneic stem cell transplantation in patients with lymphoid malignancies: P968
42. Mantle cell lymphoma and autologous stem cell transplantation: no difference in term of outcome regarding the use or not of TBI in the conditioning: P861
43. Characterization of peripheral blood stem cell grafts mobilized by G-CSF and plerixafor in comparison to G-CSF alone: O380
44. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [F] FDG-PET diffuse large B-cell lymphoma patients
45. Arrêt de l’antibiothérapie en cours de neutropénie pour fièvre d’origine indéterminée en hématologie stérile : RELAPS, une étude de cohorte bicentrique descriptive
46. Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors
47. 89 (PB079) - Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies
48. INCREASED CCND1 FISH SIGNALS ARE ASSOCIATED WITH WORSE PROGNOSIS IN MANTLE CELL LYMPHOMA
49. PF651 POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN A REAL LIFE SETTING: A SINGLE CENTER RETROSPECTIVE STUDY
50. Evaluation de la stratégie d’arrêt de l’antibiothérapie selon les recommandations de l’ECIL4 chez les patients neutropéniques traités pour une hémopathie maligne : analyse descriptive d’une série de 59 cas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.